Lyra Therapeutics, Inc.

LYRA Healthcare Biotechnology

Lyra Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $398,000.00, down 74.1% from fiscal 2024. In the quarter to December 2025, revenue fell 96.7%, EPS grew 53.0% and free cash flow grew 45.4%, each against the same quarter a year earlier.

0.19 0.00 0.00%
Market cap
$870.0K
P/E
0.0×
Fwd P/E
−0.1×
Dividend yield
—
F-score
3/9
Altman Z
−19.35
Beneish M
n/a
Dividend safety
n/a
Older periods Mar '25 Jun '25 Sep '25 Dec '25
Piotroski F-Score

+8 more TTM periods

2 2 2 3
ROE
(195.46%) (238.26%) (404.48%) (6,594.98%)
ROA
(80.40%) (52.78%) (53.81%) (56.45%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(335.41%) (184.42%) (224.73%) (370.71%)
Average Days of Receivables
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(42.88) (32.02) (19.31) (18.61)
Free Cash Flow
(56.40) (43.20) (34.14) (28.90)
Other line items

Show all line items

Columns are period end dates